Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
34
NCNA Quote, Financials, Valuation and Earnings
Last price:
$1.23
Seasonality move
:
10.84%
Day range:
$1.18 - $1.23
52-week range:
$1.17 - $19.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.81x
Volume:
37.7K
Avg. volume:
94.5K
1-year change:
-81.1%
Market cap:
$4.7M
Revenue:
--
EPS (TTM):
-$14.84
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NCNA
NuCana PLC
|
-- | -$3.95 | -- | -98.11% | $64.50 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$20.5M | -$0.18 | 4199.24% | -9.44% | $3.50 |
|
BCYC
Bicycle Therapeutics PLC
|
$7M | -$0.78 | 16.38% | -23.21% | $33.36 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | -- |
|
MREO
Mereo BioPharma Group PLC
|
-- | -$0.02 | 1109.31% | -69.36% | $7.48 |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NCNA
NuCana PLC
|
$1.21 | $64.50 | $4.7M | -- | $0.00 | 0% | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.58 | $3.50 | $148.1M | -- | $0.00 | 0% | 0.81x |
|
BCYC
Bicycle Therapeutics PLC
|
$14.69 | $33.36 | $1B | -- | $0.00 | 0% | 20.51x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$4.29 | -- | $2.5M | -- | $0.00 | 0% | 3.87x |
|
MREO
Mereo BioPharma Group PLC
|
$3.81 | $7.48 | $591.1M | -- | $0.00 | 0% | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
$0.63 | -- | $5.2M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NCNA
NuCana PLC
|
-- | 1.608 | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
38.4% | 5.180 | 20.51% | 3.54x |
|
BCYC
Bicycle Therapeutics PLC
|
-- | 1.257 | -- | 16.82x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -0.555 | -- | -- |
|
MREO
Mereo BioPharma Group PLC
|
-- | -0.254 | -- | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -0.755 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NCNA
NuCana PLC
|
-- | -$6.6M | -- | -- | -- | -$6.4M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$14.7M | -55.22% | -67.8% | -38.33% | -$54.9M |
|
BCYC
Bicycle Therapeutics PLC
|
-- | -$63.5M | -27.99% | -29.19% | -2026.05% | -$40.3M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | -- | -- |
|
MREO
Mereo BioPharma Group PLC
|
-- | -$9.1M | -- | -- | -- | -$7.5M |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -$2.6M | -- | -- | -- | -$3.5M |
NuCana PLC vs. Competitors
-
Which has Higher Returns NCNA or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -- compared to NuCana PLC's net margin of -43.07%. NuCana PLC's return on equity of -- beat Adaptimmune Therapeutics PLC's return on equity of -67.8%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana PLC-- -$2.28 -- ADAPAdaptimmune Therapeutics PLC-- -$0.06 $129.9M -
What do Analysts Say About NCNA or ADAP?
NuCana PLC has a consensus price target of $64.50, signalling upside risk potential of 5252.7%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $3.50 which suggests that it could grow by 291.62%. Given that NuCana PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe NuCana PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana PLC1 2 0 ADAPAdaptimmune Therapeutics PLC4 2 0 -
Is NCNA or ADAP More Risky?
NuCana PLC has a beta of 0.944, which suggesting that the stock is 5.593% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.179, suggesting its more volatile than the S&P 500 by 117.863%.
-
Which is a Better Dividend Stock NCNA or ADAP?
NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or ADAP?
NuCana PLC quarterly revenues are --, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $40.9M. NuCana PLC's net income of -$5.9M is higher than Adaptimmune Therapeutics PLC's net income of -$17.6M. Notably, NuCana PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus 0.81x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana PLC-- -- -- -$5.9M ADAPAdaptimmune Therapeutics PLC0.81x -- $40.9M -$17.6M
-
Which has Higher Returns NCNA or BCYC?
Bicycle Therapeutics PLC has a net margin of -- compared to NuCana PLC's net margin of -1898.43%. NuCana PLC's return on equity of -- beat Bicycle Therapeutics PLC's return on equity of -29.19%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana PLC-- -$2.28 -- BCYCBicycle Therapeutics PLC-- -$0.74 $831M -
What do Analysts Say About NCNA or BCYC?
NuCana PLC has a consensus price target of $64.50, signalling upside risk potential of 5252.7%. On the other hand Bicycle Therapeutics PLC has an analysts' consensus of $33.36 which suggests that it could grow by 127.12%. Given that NuCana PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe NuCana PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana PLC1 2 0 BCYCBicycle Therapeutics PLC5 3 0 -
Is NCNA or BCYC More Risky?
NuCana PLC has a beta of 0.944, which suggesting that the stock is 5.593% less volatile than S&P 500. In comparison Bicycle Therapeutics PLC has a beta of 0.858, suggesting its less volatile than the S&P 500 by 14.196%.
-
Which is a Better Dividend Stock NCNA or BCYC?
NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Bicycle Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or BCYC?
NuCana PLC quarterly revenues are --, which are smaller than Bicycle Therapeutics PLC quarterly revenues of $2.7M. NuCana PLC's net income of -$5.9M is higher than Bicycle Therapeutics PLC's net income of -$50.8M. Notably, NuCana PLC's price-to-earnings ratio is -- while Bicycle Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus 20.51x for Bicycle Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana PLC-- -- -- -$5.9M BCYCBicycle Therapeutics PLC20.51x -- $2.7M -$50.8M
-
Which has Higher Returns NCNA or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -- compared to NuCana PLC's net margin of --. NuCana PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana PLC-- -$2.28 -- BDRXBiodexa Pharmaceuticals PLC-- -- -- -
What do Analysts Say About NCNA or BDRX?
NuCana PLC has a consensus price target of $64.50, signalling upside risk potential of 5252.7%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of -- which suggests that it could grow by 86.87%. Given that NuCana PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe NuCana PLC is more attractive than Biodexa Pharmaceuticals PLC.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana PLC1 2 0 BDRXBiodexa Pharmaceuticals PLC0 0 0 -
Is NCNA or BDRX More Risky?
NuCana PLC has a beta of 0.944, which suggesting that the stock is 5.593% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.447, suggesting its more volatile than the S&P 500 by 44.69%.
-
Which is a Better Dividend Stock NCNA or BDRX?
NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or BDRX?
NuCana PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. NuCana PLC's net income of -$5.9M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, NuCana PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus 3.87x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana PLC-- -- -- -$5.9M BDRXBiodexa Pharmaceuticals PLC3.87x -- -- --
-
Which has Higher Returns NCNA or MREO?
Mereo BioPharma Group PLC has a net margin of -- compared to NuCana PLC's net margin of --. NuCana PLC's return on equity of -- beat Mereo BioPharma Group PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana PLC-- -$2.28 -- MREOMereo BioPharma Group PLC-- -$0.10 -- -
What do Analysts Say About NCNA or MREO?
NuCana PLC has a consensus price target of $64.50, signalling upside risk potential of 5252.7%. On the other hand Mereo BioPharma Group PLC has an analysts' consensus of $7.48 which suggests that it could grow by 96.4%. Given that NuCana PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe NuCana PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana PLC1 2 0 MREOMereo BioPharma Group PLC6 0 0 -
Is NCNA or MREO More Risky?
NuCana PLC has a beta of 0.944, which suggesting that the stock is 5.593% less volatile than S&P 500. In comparison Mereo BioPharma Group PLC has a beta of 0.935, suggesting its less volatile than the S&P 500 by 6.519%.
-
Which is a Better Dividend Stock NCNA or MREO?
NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Mereo BioPharma Group PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or MREO?
NuCana PLC quarterly revenues are --, which are smaller than Mereo BioPharma Group PLC quarterly revenues of --. NuCana PLC's net income of -$5.9M is higher than Mereo BioPharma Group PLC's net income of -$15M. Notably, NuCana PLC's price-to-earnings ratio is -- while Mereo BioPharma Group PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus -- for Mereo BioPharma Group PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana PLC-- -- -- -$5.9M MREOMereo BioPharma Group PLC-- -- -- -$15M
-
Which has Higher Returns NCNA or TCBP?
TC BioPharm (Holdings) PLC has a net margin of -- compared to NuCana PLC's net margin of --. NuCana PLC's return on equity of -- beat TC BioPharm (Holdings) PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana PLC-- -$2.28 -- TCBPTC BioPharm (Holdings) PLC-- -$5.07 -- -
What do Analysts Say About NCNA or TCBP?
NuCana PLC has a consensus price target of $64.50, signalling upside risk potential of 5252.7%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 375.74%. Given that NuCana PLC has higher upside potential than TC BioPharm (Holdings) PLC, analysts believe NuCana PLC is more attractive than TC BioPharm (Holdings) PLC.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana PLC1 2 0 TCBPTC BioPharm (Holdings) PLC0 0 0 -
Is NCNA or TCBP More Risky?
NuCana PLC has a beta of 0.944, which suggesting that the stock is 5.593% less volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NCNA or TCBP?
NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or TCBP?
NuCana PLC quarterly revenues are --, which are smaller than TC BioPharm (Holdings) PLC quarterly revenues of --. NuCana PLC's net income of -$5.9M is lower than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, NuCana PLC's price-to-earnings ratio is -- while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana PLC-- -- -- -$5.9M TCBPTC BioPharm (Holdings) PLC-- -- -- -$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 26
Power Solutions International [PSIX] is down 2.78% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 2.14% over the past day.
Buy
75
SMLR alert for Dec 26
Semler Scientific [SMLR] is down 0.14% over the past day.
